Long-term antipsychotic polypharmacy: how does it start, why does it continue?
about
Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.Factors associated with non evidence-based prescribing of antipsychoticsEffectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoateImmediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.Antipsychotic polypharmacy prescribing and risk of hospital readmission.Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
P2860
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@en
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@nl
type
label
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@en
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@nl
prefLabel
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@en
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@nl
P2860
P356
P1476
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
@en
P2093
Patrice Grech
P2860
P356
10.1177/2045125311430110
P50
P577
2012-02-01T00:00:00Z